Chimerix, Inc. (CMRX)
Apr 21, 2025 - CMRX was delisted (reason: acquired by JAZZ)
8.54
-0.01 (-0.12%)
Inactive · Last trade price on Apr 17, 2025
Chimerix Revenue
In the year 2024, Chimerix had annual revenue of $212.00K, down -34.57%. Chimerix had revenue of $57.00K in the quarter ending December 31, 2024, with 1,325.00% growth.
Revenue (ttm)
$212.00K
Revenue Growth
-34.57%
P/S Ratio
3,778.70
Revenue / Employee
$2,684
Employees
79
Market Cap
801.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 212.00K | -112.00K | -34.57% |
| Dec 31, 2023 | 324.00K | -33.50M | -99.04% |
| Dec 31, 2022 | 33.82M | 31.85M | 1,609.15% |
| Dec 31, 2021 | 1.98M | -3.39M | -63.16% |
| Dec 31, 2020 | 5.37M | -7.15M | -57.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCMRX News
- 7 months ago - Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
- 7 months ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
- 8 months ago - Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - GlobeNewsWire
- 8 months ago - CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX - Business Wire
- 8 months ago - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - PRNewsWire
- 8 months ago - Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline - Benzinga
- 8 months ago - Jazz Pharmaceuticals to buy Chimerix for $935 million - Reuters